NVO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

77.28B

-9.81%

5.816

-8.26%

76.16B

-2.47%

0.000

-100%

81.15B

+5.59%

0.000

-100%

Estimates Revision

The market is revising Downward the revenue expectations for Novo Nordisk A/S (NVO) for FY2025, with the revenue forecasts being adjusted by -2.64% over the past three months. During the same period, the stock price has changed by -11.94%.

Revenue Estimates for FY2025

Revise Downward

-2.64%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.44%

In Past 3 Month

Stock Price

Go Down

-11.94%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 57.37 USD with a low forecast of 47.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

2 Hold

1 Sell

Moderate Buy

Current: 50.370

Low

47.00

Averages

57.37

High

70.00

Current: 50.370

Low

47.00

Averages

57.37

High

70.00

HSBC

Hold

maintain

$47 -> $54

2025-12-10

Reason

HSBC

Price Target

$47 -> $54

2025-12-10

maintain

Hold

Reason

HSBC raised the firm's price target on Novo Nordisk to $54 from $47 and keeps a Hold rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

Argus

Buy -> Hold

downgrade

2025-12-08

Reason

Argus

Price Target

2025-12-08

downgrade

Buy -> Hold

Reason

Argus downgraded Novo Nordisk to Hold from Buy. The company has seen the market share of its GLP-1 drugs - Wegovy and Ozempic - decline in recent quarters and has also agreed to lower prices of these drugs in the U.S. markets, the analyst tells investors in a research note. Novo Nordisk will also soon face the entrance of generic versions of these products in certain international markets while, concurrently, some of the company's key clinical trials have "failed to impress", with the recent trials of semaglutide not confirming superiority relative to placebo in reduction of Alzheimer's disease progression, the firm added.

Argus

Buy

Hold

downgrade

2025-12-08

Reason

Argus

Price Target

2025-12-08

downgrade

Buy

Hold

Reason

Argus downgraded Novo Nordisk to Hold from Buy.

JPMorgan

Richard Vosser

Overweight

downgrade

2025-12-08

Reason

JPMorgan

Richard Vosser

Price Target

2025-12-08

downgrade

Overweight

Reason

JPMorgan analyst Richard Vosser lowered the firm's price target on Novo Nordisk to DKK 350 from DKK 500 and keeps an Overweight rating on the shares.

Morgan Stanley

Thibault Boutherin

Underweight

downgrade

$43 -> $42

2025-12-03

Reason

Morgan Stanley

Thibault Boutherin

Price Target

$43 -> $42

2025-12-03

downgrade

Underweight

Reason

Morgan Stanley analyst Thibault Boutherin lowered the firm's price target on Novo Nordisk to $42 from $43 and keeps an Underweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.

Goldman Sachs

Buy

downgrade

$60 -> $54

2025-11-28

Reason

Goldman Sachs

Price Target

$60 -> $54

2025-11-28

downgrade

Buy

Reason

Goldman Sachs lowered the firm's price target on Novo Nordisk to $54 from $60 and keeps a Buy rating on the shares.

Valuation Metrics

The current forward P/E ratio for Novo Nordisk A/S (NVO.N) is 14.36, compared to its 5-year average forward P/E of 27.71. For a more detailed relative valuation and DCF analysis to assess Novo Nordisk A/S 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

27.71

Current PE

14.36

Overvalued PE

34.83

Undervalued PE

20.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

19.82

Current EV/EBITDA

10.16

Overvalued EV/EBITDA

24.55

Undervalued EV/EBITDA

15.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

9.50

Current PS

4.48

Overvalued PS

11.90

Undervalued PS

7.09

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 112.57% over the last quarter.

Sold

Bought

Congress Trading

Congress areBuying! The buying amount has increased100%over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NVO News & Events

Events Timeline

No data

News

2.0

11:48 AMBenzinga

Novo Nordisk Slows Down as Eli Lilly Takes the Lead in Weight Loss Competition

6.5

12-15Benzinga

Bank of America Claims Eli Lilly's Obesity Drug Remains Undervalued by the Market

7.0

12-15SeekingAlpha

Centralization of Lawsuits Claiming GLP-1 Drugs Caused Blindness

People Also Watch

Frequently Asked Questions

What is Novo Nordisk A/S (NVO) stock price today?

The current price of NVO is 50.37 USD — it has increased 0.38 % in the last trading day.

What is Novo Nordisk A/S (NVO)'s business?

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

What is the price predicton of NVO Stock?

What is Novo Nordisk A/S (NVO)'s revenue for the last quarter?

Novo Nordisk A/S revenue for the last quarter amounts to 11.74B USD, increased 11.81 % YoY.

What is Novo Nordisk A/S (NVO)'s earnings per share (EPS) for the last quarter?

Novo Nordisk A/S. EPS for the last quarter amounts to 0.70 USD, decreased -22.22 % YoY.

What changes have occurred in the market's expectations for Novo Nordisk A/S (NVO)'s fundamentals?

How many employees does Novo Nordisk A/S (NVO). have?

Novo Nordisk A/S (NVO) has 76302 emplpoyees as of December 16 2025.

What is Novo Nordisk A/S (NVO) market cap?

Today NVO has the market capitalization of 223.68B USD.